Appoints Sam Raha as CEO and Mark S. Verratti as COO Effective April 30, 2025SALT LAKE CITY, Feb. 24, 2025 (GLOBE NEWSWIRE) - ...
Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, and PATHOMIQ, Inc., a ...
Gabbi’s telehealth solution provides logistics and educational support to assess breast cancer risk. Patients identified as potentially high risk are connected with a Gabbi clinician to be evaluated ...
SALT LAKE CITY (AP) — SALT LAKE CITY (AP) — Myriad Genetics Inc. (MYGN) on Monday reported a loss of $42.5 million in its fourth quarter. On a per-share basis, the Salt Lake City-based company said it ...
Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics testing and precision medicine, today announced a collaboration with Gabbi, a ...
SALT LAKE CITY - Myriad Genetics , Inc. (NASDAQ: NASDAQ:MYGN), a company specializing in molecular diagnostics and precision medicine, announced leadership changes with Sam Raha set to become ...
SALT LAKE CITY, Feb. 24, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, and PATHOMIQ, Inc., a developer of artificial ...
SALT LAKE CITY, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics testing and precision medicine, today announced that its Board of ...
SALT LAKE CITY (AP) — SALT LAKE CITY (AP) — Myriad Genetics Inc. (MYGN) on Monday reported a loss of $42.5 million in its fourth quarter. On a per-share basis, the Salt Lake City-based company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback